Lipid-Nanoparticle Based Genomic Medicines Market
完整報告名稱與涵蓋範圍
Lipid-Nanoparticle Based Genomic Medicines Market Size, Share & Trends Analysis Report By Products (D2C Gut Health Test, Probiotic Supplements, Personalized Nutrition, Microbiome Modulators, Ingredients, Medical Foods, Therapeutics), By End-User (Adult, Maternal, Infant), By Region, And By Segment Forecasts, 2025-2034
報告摘要
With a 2024 valuation of USD 2.58 Bn, the global Lipid-Nanoparticle Based Genomic Medicines Market is expected to advance to USD 38.04 Bn by 2034, demonstrating a CAGR of 31.0% during the 2025–2034 forecast window.
The Lipid-Nanoparticle Based Genomic Medicines sector involves key industry insights & findings from the report:
The shift towards customized medicine is driving the lipid-nanoparticle-based genomic medicines market. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
Growth is supported by a convergence of factors: rising awareness among end users, continuous product innovation, and the mounting emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lipid-Nanoparticle Based Genomic Medicines Market Snapshot
Chapter 4. Global Lipid-Nanoparticle Based Genomic Medicines Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Products & Trend Analysis
5.1. by MoA & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2034for the following by Products :
5.2.1. D2C Gut Health Test
5.2.2. Probiotic Supplements
5.2.3. Personalized Nutrition
5.2.4. Microbiome Modulators
5.2.5. Ingredients
5.2.6. Medical Foods
5.2.7. Therapeutics
Chapter 7. Market Segmentation 2: by End-User Estimates & Trend Analysis
7.1. by Application & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034for the following by End-User;
7.2.1. Adult
7.2.2. Maternal
7.2.3. Infant
Chapter 8. Lipid-Nanoparticle Based Genomic Medicines Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by Products , 2024-2034
8.1.3. North America Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2034
8.1.4. North America Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
8.2. Europe
8.2.1. Europe Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by Products , 2024-2034
8.2.3. Europe Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2034
8.2.4. Europe Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by Products , 2024-2034
8.3.3. Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2034
8.3.4. Asia Pacific Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
8.4. Latin America
8.4.1. Latin America Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by Products , 2024-2034
8.4.3. Latin America Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2034
8.4.4. Latin America Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by Products , 2024-2034
8.5.3. Middle East & Africa Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2034
8.5.4. Middle East & Africa Lipid-Nanoparticle Based Genomic Medicines Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Seed Health
9.2.2. ResBiotic,
9.2.3. Fitbiomics,
9.2.4. HSK Genetech,
9.2.5. Mybacs,
9.2.6. ISOThrive,
9.2.7. Nouri,
9.2.8. Bayer Consumer Health,
9.2.9. Clasado Biosciences,
9.2.10. CometBio,
9.2.11. Essential formulae,
9.2.12. ExeGi, Kerry,
9.2.13. Immune Biotech,
9.2.14. Pendulum Therapeutics,
9.2.15. Evolve Biosystems,
9.2.16. Gerber,
9.2.17. Lovebug probiotics,
9.2.18. Mommy's Bliss,
9.2.19. Zarbees,
9.2.20. Mamasselect,
9.2.21. Hyperbiotics,
9.2.22. Everidis,
9.2.23. Floraster,
9.2.24. Enfamil,
9.2.25. Culturelle,
9.2.26. Biogaia,
9.2.27. Viome,
9.2.28. Atlas Biomed,
9.2.29. Flore,
9.2.30. Bioms,
9.2.31. Ombre,
9.2.32. Biohm,
9.2.33. Affinity DNA,
9.2.34. Freshly fermented,
9.2.35. Carbiotix,
9.2.36. Troo,
9.2.37. Verisana,
9.2.38. Throne,
9.2.39. Phable,
9.2.40. Biomesight,
9.2.41. Invivo,
9.2.42. Neovos,
9.2.43. The BioArte,
9.2.44. Holobiome,
9.2.45. Bio & Me,
9.2.46. Nexbiome,
9.2.47. Holobiome,
9.2.48. Finch Therapeutics,
9.2.49. Byheart,
9.2.50. Mybiotics,
9.2.51. Vedanta Biosciences,
9.2.52. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們